nach oben

Erschienen in:

01.03.2021 | Clinical study

Universal COVID-19 vaccination cost saving unless anaphylaxis rate high

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Universal COVID-19 vaccination appears to be cost saving compared with risk-stratified vaccination unless the vaccine-related anaphylaxis rate exceeds 0.8%, according to findings of a study published in the Journal of Allergy and Clinical Immunology. …

2020 US dollars

Shaker M, et al. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated With Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. Journal of Allergy and Clinical Immunology: In Practice : 9 Mar 2021. Available from: URL: https://doi.org/10.1016/j.jaip.2021.02.054

Titel: Universal COVID-19 vaccination cost saving unless anaphylaxis rate high
Publikationsdatum: 01.03.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-93011-2

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Multiple drugs

Other adverse reaction research

Meglumine-antimonate

Amoxicillin/clavulanic acid/minocycline

Dexmedetomidine/Propofol interaction

Vismodegib